Cogent Biosciences (COGT) Interest Coverage Ratio (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Interest Coverage Ratio of 15.18 for Q1 2026, up 99.92% year-over-year from 7.59 in Q1 2025, and up 80.75% quarter-over-quarter from 78.84 in Q4 2025.
Cogent Biosciences (COGT) Interest Coverage Ratio (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Interest Coverage Ratio for 10 consecutive years, with 15.18 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 99.92% year-over-year to 15.18; the TTM figure through Mar 2026 stood at 53.03 (up 99.93% YoY), while the FY2025 annual figure was 0.45, up 64.66% from the prior year.
- Interest Coverage Ratio advanced to 15.18 in Q1 2026 per COGT's latest filing, from 78.84 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.92 in Q2 2022 and bottomed at 18733.25 in Q1 2025.
- Historically, Interest Coverage Ratio has averaged 1426.33 across 5 years, with a median of 78.84 in 2025.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio slumped 48721.25% — and 2026, when it soared 99.92%.
- Cogent Biosciences' Interest Coverage Ratio stood at 111.88 in 2022, then soared by 56.04% to 49.18 in 2023, then soared by 59.07% to 20.13 in 2024, then tumbled by 291.65% to 78.84 in 2025, then surged by 80.75% to 15.18 in 2026.
- Business Quant data shows COGT's Interest Coverage Ratio at 15.18 in Q1 2026, 78.84 in Q4 2025, and 14.5 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | -15.69 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.69 |
| Mar 31, 2026 | -15.18 |
| Dec 31, 2025 | -78.84 |
| Sep 30, 2025 | -14.50 |
| Jun 30, 2025 | -240.71 |
| Mar 31, 2025 | -18,733.25 |
| Dec 31, 2024 | -20.13 |
| Jun 30, 2024 | -335.35 |
| Mar 31, 2024 | -990.54 |
| Dec 31, 2023 | -49.18 |
| Sep 30, 2023 | -346.40 |
| Jun 30, 2023 | -448.43 |
| Dec 31, 2022 | -111.88 |
| Sep 30, 2022 | -2.90 |
| Jun 30, 2022 | -0.92 |
| Mar 31, 2022 | -6.84 |
| Dec 31, 2021 | -31.19 |
| Sep 30, 2021 | -42.81 |
| Jun 30, 2021 | -3.79 |
| Mar 31, 2021 | -16.58 |